GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Atovaquone oral suspension (Mepron)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons

Mepron

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

MEPRON suspension - U.S. label; renal pharmacokinetics not studied

Product / population
Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.
Renal measure
No renal-function dose bands specified for this summary.

Dosing / renal protocol and limits

For adults unable to tolerate TMP-SMX, PJP prevention uses 1500 mg (10 mL) orally once daily with food. Mild-to-moderate PJP treatment uses 750 mg (5 mL) twice daily with food for 21 days. The suspension is 750 mg/5 mL. Severe PJP is outside the studied treatment scope.

The label states that pharmacokinetics have not been studied in renal impairment. It does not supply a CrCl-based adjustment or dialysis protocol. The separately displayed UCSF dialysis regimen is therefore institutional guidance, not an FDA-confirmed renal regimen. Review absorption problems, interacting drugs and the March 2026 severe-cutaneous-reaction warning.

Source revision: DailyMed updated 2026-03-20. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b426b6bf-f07e-4580-97ae-dfca1ddf5b8f

Scope: Locally included source-specific summary. Regimen differences are not automatically resolved. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Official product label

MEPRON suspension - U.S. label; renal pharmacokinetics not studied

Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.

Renal method: No renal-function dose bands specified for this summary.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Professional guidance

UCSF - atovaquone in dialysis

Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: Institutional dialysis regimen; no numeric renal adjustment bands.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Handbook

Renal Drug Handbook, 5th edition - Atovaquone

Historical adult renal/RRT summary. U.S. product identity anchored to the separate locally included DailyMed label. This is not a current U.S. product label.

Renal method: Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.
Retrieved: 2026-09-05

Read local renal result

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Handbook source

Renal Drug Handbook, 5th edition - Atovaquone

Historical adult renal/RRT summary. U.S. product identity anchored to the separate locally included DailyMed label. This is not a current U.S. product label.

Method: Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.

Historical renal / replacement-therapy guidanceRead this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeMEPRON suspension - U.S. label; renal pharmacokinetics not studiedUCSF - atovaquone in dialysisRenal Drug Handbook, 5th edition - Atovaquone
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

The U.S. label does not establish renal pharmacokinetics. UCSF and the handbook provide additional recommendations; these cannot be called matching renal-label protocols.

Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b426b6bf-f07e-4580-97ae-dfca1ddf5b8f

Product and population scope

Adult Atovaquone oral suspension (Mepron). Use only the product, route, indication and renal-replacement setting explicitly stated in the source protocol selected below. Sources are alternatives to compare, not ingredients of a blended regimen.

SCOPE-atovaquone · Source section: Editorial scope; each clinical recommendation is separately attributed belowRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

MEPRON suspension - U.S. label; renal pharmacokinetics not studied

Open original reference

Open / share this exact local source

NIH/NLM DailyMed - U.S. product labeling · Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.

Renal method: No renal-function dose bands specified for this summary.
Source date: DailyMed updated 2026-03-20.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

For adults unable to tolerate TMP-SMX, PJP prevention uses 1500 mg (10 mL) orally once daily with food. Mild-to-moderate PJP treatment uses 750 mg (5 mL) twice daily with food for 21 days. The suspension is 750 mg/5 mL. Severe PJP is outside the studied treatment scope.

The label states that pharmacokinetics have not been studied in renal impairment. It does not supply a CrCl-based adjustment or dialysis protocol. The separately displayed UCSF dialysis regimen is therefore institutional guidance, not an FDA-confirmed renal regimen. Review absorption problems, interacting drugs and the March 2026 severe-cutaneous-reaction warning.

RDM30-073-atovaquone-1 · Source locator: MEPRON suspension - U.S. label; renal pharmacokinetics not studied; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b426b6bf-f07e-4580-97ae-dfca1ddf5b8f
Retrieved
2026-09-05
DailyMed Set ID
b426b6bf-f07e-4580-97ae-dfca1ddf5b8f
Renal-function method
No renal-function dose bands specified for this summary.
Source date/version
DailyMed updated 2026-03-20.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
bd24a19c010b7cf3c1f2adfcc71bfd194c1b6fd29df99090c96d49c04ec5033e
Separate handbook layer

Renal Drug Handbook cross-check

Handbook

Renal Drug Handbook, 5th edition - Atovaquone

Open / share this exact local source

UK Renal Pharmacy Group / CRC Press · Historical adult renal/RRT summary. U.S. product identity anchored to the separate locally included DailyMed label. This is not a current U.S. product label.

Renal method: Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.
Source date: 5th edition; 2019 copyright; historical reference
Retrieved: 2026-09-05

Historical handbook cross-check; not a current U.S. protocol

Historical renal / replacement-therapy guidance

The 20-50, 10-20 and <10 mL/min bands retain the usual indication-specific dose. At <10 mL/min the book adds caution. Its PCP regimen is 750 mg twice daily for 21 days with food. HD/PD: usual dose, described as not dialyzed; high-flux removal unknown; continuous removal unlikely. Unlike these handbook suggestions, the selected U.S. label says renal pharmacokinetics have not been studied.

HB30-atovaquone-1 · Source locator: Printed page 97: renal impairment, RRT and other information

Source-specific limits

Separate source recommendation, not proof of agreement or contemporary clinical validation. Dialysis predictions are retained with their original certainty.

Source identity and provenance
Retrieved
2026-09-05
Handbook page
5th edition, printed p. 97; uploaded PDF p. 116
Renal-function method
Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.
Source date/version
5th edition; 2019 copyright; historical reference
U.S. product identity basis
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b426b6bf-f07e-4580-97ae-dfca1ddf5b8f
Hash meaning
Local paraphrase; original book not redistributed
Local summary SHA-256
98fd146e209ab0cc4e025341d5be58c572a2e732dba112029b329452c048b0dd
Separate professional-source layer

University and professional protocols

Professional

UCSF - atovaquone in dialysis

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: Institutional dialysis regimen; no numeric renal adjustment bands.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

For adults intolerant of trimethoprim/sulfamethoxazole, Pneumocystis prevention uses 1500 mg orally daily with food. Mild-disease treatment uses 750 mg twice daily with food. The source's dialysis table retains these same regimens.

This is institutional dialysis guidance, not proof that an official label studied renal pharmacokinetics. Use the severity-specific Pneumocystis pathway; do not apply this mild-disease regimen to severe disease.

RDM30-048-atovaquone-1 · Source locator: UCSF - atovaquone in dialysis; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/atovaquone
Retrieved
2026-09-05
Renal-function method
Institutional dialysis regimen; no numeric renal adjustment bands.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
9f24342b897a490e126efddcd322cd71f8698e2b294aa29361b109ae4e3c1d9a

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 1 professional, 1 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b426b6bf-f07e-4580-97ae-dfca1ddf5b8f
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
a79346a8c901e5e5a4c66ab110204e63391546655f31fb562c6b430b66e21dc3
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report